admin 
Dubai: Emirates Drug Establishment (EDE) has approved “Wegovy Semaglutide” from Novo Nordisk, as a once-daily oral treatment for long-term weight management in adults with obesity, or overweight associated with co-morbid health conditions.
The drug belongs to the GLP-1 receptor class, and works to reduce weight and maintain its results when used, in conjunction with a low-calorie diet and increased physical activity, thereby contributing to improving health outcomes for the target groups.
Clinical data showed that the treatment reduces the risk of major cardiovascular risks in patients most susceptible to them, including cardiovascular death, heart attacks, and strokes.
The UAE is the second country globally to approve this drug, a step which reflects its leadership in adopting modern therapeutic innovations and providing early access to them.
Dr Fatima Al Kaabi, Director General of EDE, affirmed that the approval of the oral formulation of “Wegovy” reflects the EDE’s role in developing the pharmaceutical system.
She added: “This step embodies the UAE’s commitment to adopting the latest pharmaceutical innovations and developing a flexible regulatory environment which ensures these treatments reach patients, according to the highest standards, thereby contributing to improving treatment outcomes and quality of care.”
The approval of the drug allegedly reflects the UAE’s direction towards enhancing health awareness of the importance of early obesity management and reducing its health complications.
Venkat Kalyan, General Manager of Novo Nordisk Gulf, said: “The collaboration with the EDE reflects a shared commitment to providing innovative and reliable therapeutic solutions.
“Wegovy Semaglutide has a solid safety record and widespread trust among medical communities, and its availability in a daily oral form enhances ease of use and supports patient adherence to treatment.”
